The pharma industry’s powerful Washington, D.C. trade association decreased by nearly two dozen companies after changing its membership rules amid the debate over U.S. drug prices, according to a Bloomberg article.
Pharmaceutical Research and Manufacturers of America (PhRMA) will require that members spend at least $200 million a year on research and development and that their R&D spending is at least 10 percent of global sales. The changes follow a three-month review that has already seen several member companies leave the lobbying group, the story said.
Read the full article